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Abstract
Background: Aspirin (ASA) use has been associated with improved breast cancer survival in several prospective
studies.
Methods: We conducted a nested case–control study of ASA use after a breast cancer diagnosis among women
using Swedish National Registries. We assessed prospectively recorded ASA exposure during several different time
windows following cancer diagnosis using conditional logistic regression with breast cancer death as the main
outcome. Within each six-month period of follow-up, we categorized dispensed ASA doses into three groups: 0, less
than 1, and 1 or more daily doses.
Results: We included 27,426 women diagnosed with breast cancer between 2005 and 2009; 1,661 died of breast
cancer when followed until Dec 31, 2010. There was no association between ASA use and breast cancer death
when exposure was assessed either shortly after diagnosis, or 3–12 months before the end of follow-up. Only during
the period 0–6 months before the end of follow-up was ASA use at least daily compared with non-use associated
with a decreased risk of breast cancer death: HR (95% CI)= 0.69 (0.56-0.86). However, in the same time-frame, those
using ASA less than daily had an increased risk of breast cancer death: HR (95% CI) =1.43 (1.09-1.87).
Conclusions: Contrary to other studies, we did not find that ASA use was associated with a lower risk of death
from breast cancer, except when assessed short term with no delay to death/end of follow-up, which may reflect
discontinuation of ASA during terminal illness.
Keywords: Aspirin, Breast neoplasms, Survival, Prospective study, Sweden, Registries
Background
In Western countries, increasingly effective adjuvant
systemic treatment has entailed a gradual improvement
in breast cancer survival [1]. Nevertheless, even breast
cancer that is considered to have a good prognosis (node-
negative, hormone –responsive) has a substantial risk of
recurring within 10 years, 7-30% depending on its genetic
signature [2]. Breast cancer mortality still dominates the
cancer landscape in Western countries and to an increas-
ing extent also in the developing world [3]. Hence, new
and affordable therapies are urgently needed. There is
accumulating pre-clinical and epidemiologic data which
support a protective effect for aspirin (acetylsalicylic
acid – ASA) – and perhaps some other non-steroidal anti-
inflammatory drugs (NSAIDs) in breast cancer survival
by an amount that rivals the benefits of currently used
cancer specific therapies. Postulated mechanisms include
the inhibition of prostaglandins which stimulate angiogen-
esis, inhibit apoptosis, and stimulate aromatase activity
and thus increase estrogen levels; ASA may also inhibit
platelet-induced adhesion of circulating tumor cells that
initiate metastases [4]. Ultimately however, the mechanism
is not known.
In the absence of randomized trials, large prospective
observational studies remain important to advance this
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population-based registers allowing a prospective nation-
wide study with drug intake ascertained through a pre-
scription register. We hypothesized that women with
breast cancer who took ASA would experience a lower
risk of death from breast cancer compared to similar
women not taking ASA.
Methods
Study cohort
Using the Swedish National Cancer Register, we identified
33,697 female patients with a first incident breast cancer
diagnosis between April 1, 2005 and December 31, 2009.
We excluded 6,244 patients who had a record of another
cancer diagnosis (except non-melanoma skin cancer) prior
to breast cancer, 22 cases diagnosed at autopsy, and 5 indi-
viduals with erroneous coding of dates of last follow up.
Reporting of cancers by clinicians and pathologists has
been required by Swedish law since 1958, and the com-
pleteness of the Cancer Registry is now approaching 100%
for breast cancer. Using the National Registration Num-
bers assigned to all Swedish residents, the cohort was fur-
ther linked with other nation-wide registers including the
Prescribed drug Registry, the Cause of death Registry, the
Patient Registry and the LISA (longitudinal integration
database for health insurance and labor market studies)
registry including information on highest achieved educa-
tional level (≤9y e a r s ,1 0 –12 years, >12 years) [5].
Linkage to the Population Registry allowed us to censor
the 44 women who were lost to follow-up because they
moved out of the country. Linkage to the death registry
allowed us to achieve virtually complete follow-up with
regard to vital status and to ascertain date of death as
well as cause of death up to Dec 31, 2010.
The study was approved by the Regional Ethics Com-
mittee, Karolinska Institutet, Stockholm Sweden (2007/
1335-31/4). No patient consent was needed.
Study design
Within the final cohort of 27,424 patients with a first in-
cident breast cancer diagnosed during the study period,
we used a nested case–control design to investigate the
association between the dispensing of ASA at different
time intervals after breast cancer diagnosis and risk of
breast cancer death. In the main analysis, cases were all
individuals in the cohort experiencing death due to
breast cancer during the study period starting from
3 months following breast cancer diagnosis. We did not
consider exposure or outcome events during the first
three months after diagnosis since most women are ex-
pected to use pain killers including ASA immediately
following surgery. Death due to breast cancer was de-
fined as having breast cancer as the main cause of death.
For each case we randomly selected 2 controls via
risk-set sampling using time since diagnosis as the time
scale. Additionally, cases and controls were matched on
age and calendar year of breast cancer diagnosis. Since
we sampled controls at the time of the event of the case,
we took drop outs and other deaths into account. The
end of follow-up for each matched risk set was consid-
ered to be the time of death for the case. In analyses
stratified by stage at breast cancer diagnosis (stage I, II,
III-IV), new controls were sampled to the cases in each
stratum and additionally matched on breast cancer stage.
In a secondary analysis, cases were defined as breast
cancer patients who died of non-breast-cancer related
causes, and controls were sampled from within the co-
hort using a similar procedure as described above.
Classification of drug intake
The Swedish Prescription registry has recorded all pre-
scriptions dispensed at Swedish pharmacies prospectively
beginning from 1
st of July 2005 [6]. In the prescription
registry, we ascertained any dispensing of prescribed low
dose ASA during the entire period of follow-up. Our
definition of dispensed ASA was limited to daily doses
of 75 or 160 mg (ATC codes B01AC06, 30 and 56), as
these doses represent 90% of all ASA forms sold nation-
a l l y ,a n da r ea v a i l a b l eo n l yb yp r e s c r i p t i o n .
We classified drug intake according to the following
principles: within each six-month period of follow-up,
we added up the total number of dispensed ASA and
categorized drug intake into three different groups; unex-
posed individuals (0 daily doses), partially exposed individ-
uals (less than 1 daily dose) and fully exposed individuals
(1 or more daily doses of either 75 or 160 mg). To account
for possible variation in the dispensing of drugs during
follow-up, exposure was assessed during different time
windows; 3–9 months following diagnosis, 6–12 months
before end of follow-up, 3–9 months before end of follow-
up and, 0–6 months before end of follow-up. Further-
more, we examined cumulative exposure as the percent-
age of follow-up time as exposed in three different
analyses. The date of entry (i.e. 3 months following
diagnosis) was used as starting point in all three ana-
lyses, and the proportion of follow-up time as exposed
was summed up to 6 months before end of follow-up,
3 months before end of follow-up, or up to the end of
follow-up, respectively.
Non-aspirin NSAIDs may also affect breast cancer
survival, and NSAID use may correlate with ASA use.
Therefore, since NSAID use may confound the associ-
ation tested, we assessed NSAID dispensings (ATC codes
starting with M01A) in a similar fashion to ASA, as de-
scribed above, in order to be able to adjust for NSAID use
as a covariate (yes/no in each time window investigated).
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The Swedish National Board of Health and Welfare has
compiled data on individual hospital discharges in its
Patient registry which has had nation-wide coverage
since 1987 as previously described [7]. Besides national
registration number, each record contains medical data
including diagnosis at discharge according to the Inter-
national Classification of Diseases X
th Revision. Since
2001, this register also records visits in specialized out-
patient care. Because of concern that underlying diseases
might confound an association between drug intake and
breast cancer survival, we linked the entire study cohort
to the Patient registry for the period 1987 to 2009. Co-
morbidity was assessed in two major groups: diseases
for which ASA use is recommended (cardiovascular, in-
flammatory and cerebrovascular disorders) and diseases
where ASA may be counter-indicated (thromboembolism,
peptic ulcer disease, chronic liver failure, and asthma).
Since the Patient Registry is confined to records of hos-
pital admissions and/or specialized outpatient visits and
not visits to the general practitioner, we consider the
comorbidity assessment to represent severe disorders.
Statistical analysis
We analyzed the association between low-dose ASA and
risk of breast cancer death, using conditional logistic re-
gression, with one analysis for each exposure window
investigated. All models were adjusted for co-morbid
diseases and educational level as a proxy for socioeco-
nomic status. For each analysis the co-morbid diseases
status was evaluated before the start of each exposure
window, thus allowing co-morbid status to vary between
analyses. For analysis per each time window, only cases
(and the respective controls) that were followed-up long
enough to experience the whole exposure window were
included. For example, to be included in the analysis of
exposure 3–9 months before end of follow-up the case
had to survive at least 9 months from entry. Since we
use a nested case–control design with risk-set sampling
of controls, we were in fact measuring the same quan-
tity as in a time-to-event analysis. By sampling controls
among those at risk at each time of an event, we have
controlled for follow-up time, and the estimated odds
ratios from the conditional logistic regression were there-
fore regarded and reported as hazard ratios [8].
Results and discussion
Results
Table 1 shows the characteristics of women diagnosed
with incident breast cancer during the study period. Of
the 27,426 women diagnosed, 1,661 of them died of
breast cancer during a median follow-up of 2.57 years.
In addition, 1,371 died of other causes. A relatively small
proportion (12.6%) had severe co-morbid conditions
associated with recommendations to use ASA or not.
Figure 1 presents an overview of the time periods of
exposure assessment that are shown in the subsequent
tables. Each method of exposure assessment is labeled
with the letters A – G.
Overall survival in the group was 94% at 2 years and
83% at 5 years after diagnosis. (Additional file 1: Figure S1)
Approximately 10% of the cases and controls (10.8%
among the cases and 10.2% among controls) changed
ASA exposure category from baseline to the next-to-last
time window assessed (9–3 months before end of follow-
up). Comparing baseline to the last time window (6–0
months before end of follow-up), 12.8% of the cases and
10.8% among the controls had changed exposure status.
Table 1 Characteristics of women with incident breast
cancer in Sweden April 1, 2005 to December 31, 2009
Characteristic Breast cancer
patients N (%)
Breast cancer
deaths N (%)
Total number 27426 1661 (6.1)
Follow-up time, years, median (range) 2.57 (0–5.25) 1.48 (0–4.50)
Age at diagnosis, years
20-29 104 (0.4) 11 (10.6)
30-39 1042 (3.8) 73 (7.0)
40-49 4098 (14.9) 175 (4.3)
50-59 6259 (22.8) 283 (4.5)
60-69 7869 (28.7) 329 (4.2)
70-79 4441 (16.2) 323 (7.3)
80-89 3037 (11.1) 370 (12.2)
90≤ 576 (2.1) 97 (16.8)
Median (range) 62 (20–102) 68 (21–102)
Calendar year of diagnosis
2005 4267 (15.6) 451 (10.6)
2006 5769 (21.0) 477 (8.3)
2007 5721 (20.9) 359 (6.3)
2008 5829 (21.3) 250 (4.3)
2009 5840 (21.3) 124 (2.1)
Stage
I 12645 (46.1) 158 (9.5)
II 9715 (35.4) 670 (40.3)
III 1381 (5.0) 316 (19.0)
IV 438 (1.7) 227 (13.7)
Missing 3247 (11.8) 290 (17.5)
Severe comorbidity
Disorders associated, with use of
ASA*
2334 (8.5) 362 (15.5)
Disorders associated, with decreased
use of ASA**
1116 (4.1) 182 (16.3)
*Hospitalizations or specialized outpatient visits for chronic inflammatory,
cardiovascular or cerebrovascular disorders.
**Hospitalizations or specialized outpatient visits for asthma, peptic ulcers,
chronic liver disease or venuous thromboembolism.
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breast cancer death, with ASA intake assessed at varying
6-month periods between diagnosis and death/end of
follow-up. When we excluded exposure during the first
3 months after diagnosis (presumed to be the post-
operative period), the basel i n ee x p o s u r ea s s e s s m e n tw a s
considered to be 3 to 9 months after diagnosis (Expos-
ure Period A). Exposure Periods B, C, and D were 12 to
6 months, 9 to 3 months, and 6 to 0 months before
death/end of follow-up. Table 2 contains two types of
models. Model 1 was adjusted only for age and calendar
year at diagnosis, and time since diagnosis. Model 2 was
additionally adjusted for co-morbid disease and education
level. We found a modest change in the hazard ratios (HR)
between models 1 and 2, indicating a modest amount of
confounding by disease co-morbidity and education.
Diagnosis of 
breast cancer
Death/End 
of follow-up
Time (months) 
following diagnosis
03 9
Time (months) before
death/end of follow-up
3 6 9 12 0
AB
C
D
E
F
G
Figure 1 Overview of time periods of exposure assessment.
Table 2 Relative risk (HRs and 95% Confidence Intervals, CI) of breast cancer death in association with dispensed ASA
dose at different time periods following breast cancer diagnosis using a nested case–control design
Period ASA dose Cases Controls Model 1 Model 2
HR (95% CI) HR (95% CI)
A - Baseline (3 to 9 months after diagnosis)
(n=1521) (n=3042)
0 1235 (81.2) 2481 (81.6) 1.00 1.00
<1 daily dose 78 (5.1) 146 (4.8) 1.08 (0.81; 1.44) 1.13 (0.84; 1.52)
≥ 1 daily dose 208 (13.7) 415 (13.6) 1.01 (0.84; 1.23) 0.97 (0.79; 1.18)
B - 12 to 6 months before end of follow-up
(n=1211) (n=2422)
0 964 (79.6) 1961 (81.0) 1.00 1.00
<1 daily dose 72 (5.9) 138 (5.7) 1.08 (0.80; 1.46) 1.05 (0.77; 1.44)
≥ 1 daily dose 175 (14.5) 323 (13.3) 1.12 (0.90; 1.38) 1.02 (0.81; 1.28)
C - 9 to 3 months before end of follow-up
(n=1380) (n=2760)
0 1102 (79.9) 2216 (80.3) 1.00 1.00
<1 daily dose 81 (5.9) 152 (5.5) 1.07 (0.81; 1.42) 1.00 (0.74; 1.34)
≥ 1 daily dose 197 (14.3) 392 (14.2) 1.01 (0.83; 1.24) 0.93 (0.75; 1.15)
D - 6 to 0 months before end of follow-up
(n=1521) (n=3042)
0 1220 (80.2) 2420 (79.6) 1.00 1.00
<1 daily dose 120 (7.9) 159 (5.2) 1.49 (1.16; 1.92) 1.43 (1.09; 1.87)
≥ 1 daily dose 181 (11.9) 463 (15.2) 0.77 (0.63; 0.93) 0.69 (0.56; 0.86)
Model 1: Logistic regression model with adjustment for the matching factors age at diagnosis, calendar year of diagnosis, and time since diagnosis.
Model 2: Additional adjustment for comorbidity (in groups of disorders associated with increased or decreased use of ASA) and highest obtained educational level
(≤9 years, 10–12 years, >12 years).
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cancer death in Exposure Periods A, B, and C. For Ex-
posure Period D only (6 to 0 months before end of
follow-up), was there a decreased risk of breast cancer
death among those using ASA at least daily compared to
non-users; HR (95% CI) =0.69 (0.56-0.86). However, we
found no evidence of a dose–response association in this
time-window, as those using ASA less than daily had an
increased risk of breast cancer death: HR (95% CI) =
1.43 (1.09-1.87).
In Table 3 we show the results of assessing cumula-
tive ASA intake beginning with the baseline period.
We assessed the result of ending this cumulative ASA
exposure at varying times before the end of follow-up.
In Exposure Periods E, F, and G we ended assessment
of cumulative ASA exposure 6 months, 3 months, and
0 months before the end of follow-up, respectively.
ASA intake was assessed as a percentage of the follow-
up time, and was categorized as 0%, >0 – 25%, >25 –
50%, >50-75%, and >75% of the time. Models were the
same as in Table 2. When assessed cumulatively, there
was no association between ASA intake and risk of breast
cancer death regardless of when exposure assessment
ended. In addition, there was no evidence of a dose re-
sponse with increasing percentages of time using ASA.
The analyses in Tables 2 and 3 were repeated with
additional adjustment for stage at diagnosis (4 stages);
there was no material change in the results (data not
shown). In addition, the analyses in Tables 2 and 3 were
also repeated with additional adjustment for use of other
NSAIDs; again results did not materially change (data
not shown). The hazard for breast cancer death for non-
ASA NSAID use (compared to non-use) in models ad-
justed for all factors (including ASA use) was greater
than one and increased as the end of follow-up was
approached (Additional file 2: Table S3).
In secondary analyses, we assessed whether results dif-
fered by stage at diagnosis. We repeated the analysis in
Table 2, stratified by the categories Stage I, Stage II, and
Stages III+IV (Additional file 2: Table S1). The results
did not differ substantially from the non-stratified analyses
(those in Table 2).
We assessed whether ASA intake was associated with
non-breast cancer causes of death in an analysis similar
to that of Table 2 (Additional file 2: Table S2). Compared
to non-use, intake of ASA was associated with increased
Table 3 Relative risk (HRs and 95% Confidence Intervals, CI) of breast cancer death in association with cumulative ASA
dispensing defined as percent of time as exposed from breast cancer diagnosis to end of follow-up
Period ASA dose Cases Controls Model 1 Model 2
HR (95% CI) HR (95% CI)
E - Up to 6 months before end of follow-up
(n=1521) (n=3042)
0% 1206 (79.3) 2439 (80.2) 1.00 1.00
>0 – 25% 23 (1.5) 40 (1.3) 1.18 (0.69; 1.99) 1.28 (0.74; 2.21)
>25 – 50% 22 (1.5) 44 (1.4) 1.02 (0.60; 1.74) 1.18 (0.68; 2.04)
>50 – 75% 29 (1.9) 63 (2.1) 0.94 (0.60; 1.47) 0.99 (0.63; 1.58)
>75% 241 (15.8) 456 (15.0) 1.08 (0.90; 1.30) 1.05 (0.87; 1.28)
F - Up to 3 months before end of follow-up
(n=1661) (n=3322)
0% 1298 (78.1) 2622 (78.9) 1.00 1.00
>0 – 25% 31 (1.9) 48 (1.4) 1.32 (0.83; 2.10) 1.47 (0.91; 2.38)
>25 – 50% 26 (1.6) 60 (1.8) 0.88 (0.55; 1.41) 0.98 (0.60; 1.59)
>50 – 75% 41 (2.4) 74 (2.2) 1.13 (0.76; 1.66) 1.18 (0.80; 1.76)
>75% 265 (16.0) 518 (15.5) 1.04 (0.88; 1.24) 1.00 (0.83; 1.20)
G - Up to end of follow-up
(n=1661) (n=3322)
0% 1266 (76.2) 2572 (77.4) 1.00 1.00
>0 – 25% 43 (2.6) 57 (1.7) 1.56 (1.04; 2.34) 1.65 (1.08; 2.53)
>25 – 50% 34 (2.0) 64 (1.9) 1.09 (0.71; 1.68) 1.20 (0.77; 1.85)
>50 – 75% 54 (3.3) 89 (2.7) 1.25 (0.88; 1.78) 1.27 (0.89; 1.82)
>75% 264 (15.9) 540 (16.3) 1.00 (0.84; 1.19) 0.96 (0.80; 1.16)
Model 1: Logistic regression model with adjustment for the matching factors age at diagnosis, calendar year of diagnosis, and time since diagnosis.
Model 2: Additional adjustment for comorbidity (in groups of disorders associated with increased or decreased use of ASA) and highest obtained educational level
(≤9 years, 10–12 years, >12 year).
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for the earlier Exposure Periods A, B, and C and less so
for Exposure Period D, with evidence of a dose–response
in periods A, B and C. For example, for the baseline (Ex-
posure Period A), the HR (95% CI) for no intake, <1 daily
dose, and >1 daily dose were 1.00 (reference), 1.23 (0.96-
1.58), and 1.35 (1.14-1.60), respectively.
Discussion
In this nested case–control study using linked prospect-
ively recorded Swedish cancer registry, death registry, and
national pharmacy data, we found little evidence that ASA
intake among women diagnosed with breast cancer re-
duces risk of breast cancer death. After assessing ASA
exposure multiple different ways, we found that only
when ASA intake was assessed short term without any
delay (i.e., in the six-month-period preceding death/end
of follow-up) was it associated with a reduced risk of
breast cancer death similar in magnitude to that reported
in most other studies assessing ASA and/or NSAIDs
[9-13]. This result is concerning for the possibility of con-
founding by indication: women who are ill from metastatic
cancer may forgo ASA prescribed primarily to prevent
heart disease, likely considered less relevant as they ap-
proach death from breast cancer. It may also be that our
exposure ascertainment fails when patients are admitted
to hospices or other forms of terminal care where drugs
use will not be recorded in the Prescribed Drug Registry.
Also, we found an increasing hazard of breast cancer
death with non-ASA NSAID use as the end of follow-up
approached. This result is best explained by women using
more NSAIDs for pain control as they approached death,
i.e., confounding by indication.
Limitations of our study include the following: ASA is
available over-the-counter in Sweden as in all countries.
Since we relied on pharmacy records, we undoubtedly
misclassified ASA use as many categorized as non-users
by pharmacy records were likely users. However, low-
dose ASA (for example to prevent heart disease) consti-
tutes close to 90% of all ASA sold in Sweden, and low-
dose forms are only available through prescription [14].
With the data at hand, we were only able to classify dose
based on the amount of tablets dispensed in relation to
recommended daily dose, and we could not distinguish
between dispensings of tablets of 75 mg or 160 mg ASA
(the two options of low-dose ASA that exist in Sweden).
In addition, we regret not having access to additional
clinical data on breast cancer characteristics and treat-
ment for further adjustment, although we do not think
that these factors necessarily represent strong potential
confounders of ASA use and breast cancer prognosis be-
yond stage.
We must consider why our results differ from other
prospective studies of the same question. Of the four
published studies, The Iowa Women’s Health Study re-
ported a RR (95% CI) of breast-cancer death, 0.53 (0.30-
0.93) for women with breast cancer using ASA compared
to nonusers [10], and the Nurses’ H e a l t hS t u d yr e p o r t e da
similar result: 0.51 (0.41-0.65) [11]. The Life After Cancer
Epidemiology (LACE) cohort reported no association with
ASA (RR (95% CI)=1.09 (0.74-1.61)) using recurrence as
the outcome, but a significantly lower recurrence for
current NSAID intake, RR (95% CI)=0.56 (0.33-0.95) [9].
A New York based cohort of women with breast cancer
reported no association of pre-diagnostic ASA use with
breast cancer death, RR (95% CI)=0.82 (0.54-1.24) [15].
Firstly, misclassification of ASA use mentioned in the
limitations above (over-the-counter ASA users misclas-
sified as non-users, and our inability to distinguish be-
tween doses of ASA) would tend to underestimate any
ASA effect.
Secondly, follow-up time in the two previous studies
null for ASA intake [9,15], and in our present study, was
considerably less than that for the two studies which
found an ASA advantage [10,11]; mean 2.5 years for LACE,
[9], median 2.6 years for the current study, mean 7.3 years
for the New York cohort [15], and mean 8.3 years for the
Iowa Women’s Health Study [10], and maximum 30 years
for the Nurses’ Health Study [11] which may explain these
differing results. Another aspect of potential importance
for the discrepant observations is varying time periods of
exposure assessment. In the present study, we used the
nested case–control design to closely examine the effect of
timing of ASA use. Only in the last period of follow-up
did we observe a reduced risk among daily users, possibly
explained by decreased intake due to terminal illness or
in-hospital drug administration, although a true effect can-
not be excluded. Along these lines, in one of the studies
reporting a reduced risk with ASA, the inverse association
was observed with current but not past use [11]. However,
it should be noted that the association with current use
in that study remained in analyses of risk of cancer re-
currence, likely less affected by changes towards the
end of life.
Our lack of finding a cumulative dose or duration effect
was similar to one other published study [11]. The fact
that as much as 55% of women who died in our study,
died of breast cancer could be expected due to the short
follow-up (median 2.6 years), as the peak of recurrences
occurs within the first 5 years after diagnosis, particu-
larly among those whose tumors are hormone receptor
negative [16].
Recently published data from randomized trials provide
intriguing evidence for the effect of ASA on cancer recur-
rence. Data was pooled from 5 large United Kingdom tri-
als of ASA to prevent vascular disease and examined for
the effect of ASA on cancer metastases presenting during
the trials or after they ended. Those subjects treated with
Holmes et al. BMC Cancer 2014, 14:391 Page 6 of 8
http://www.biomedcentral.com/1471-2407/14/391ASA had a substantially reduced risk of metastatic
adenocarcinoma (of any site) (RR=0.52, 95% CI=0.35-
0.75). Although it was difficult to examine individual
cancer sites because of small numbers, there was a sugges-
tion of reduced case-fatality for breast cancer (RR=0.16,
95% CI=0.02-1.19) [12].
We found an increased risk of non-breast cancer death
for ASA users. This makes sense because ASA users are
most likely taking it as secondary prevention for cardio-
vascular disease. It may also indicate that we could not
fully adjust for co-morbidity. However, the extent to
which co-morbidity is associated with breast cancer
survival, potentially leading to residual confounding in
our data, is unclear. We also found an increased risk of
breast cancer death among patients taking less than 1
dose/day on average, during the 6 months prior to death
(or corresponding date for matched controls). However,
this may be due to reverse causation, as terminally ill
breast cancer patients might stop secondary prevention
for cardiovascular disease or be admitted to hospital for
terminal care, and consequently their medication would
not be recorded in the Swedish prescription registry,
since the register does not cover drugs distributed in
hospitals.
Conclusion
In conclusion, in this population-based Swedish register
study, we did not find that use of ASA among women
with breast cancer was associated with a lower risk of
death from breast cancer. This is contrary to results
from some but not all other prospective cohort studies.
We found that ASA intake was associated with a reduced
risk of breast cancer death only when it was assessed short
term with no delay to death or end of follow-up, and also
that non-breast cancer deaths were higher among ASA
users. Because of these two findings, we speculate that
the phenomenon of confounding by indication may be
contributing to the conflicting results from prospective
studies.
We suggest a randomized trial of ASA in women with
breast cancer specifically with breast cancer death as the
outcome, for efficiency limited to women with stages II
and III tumors at higher risk of recurrence. Because of the
risk of serious gastrointestinal bleeding or hemorrhagic
stroke, ASA is currently recommended to prevent heart
disease only among those women considered to be high
risk (previous myocardial infarction or stroke, with angina
or coronary artery stent or revascularization, or with
diabetes over age 60). Such women for whom ASA is in-
dicated would ethically have to be excluded from a trial
of ASA for breast cancer survival. A randomized trial
will be the only way to sort out the issues of confound-
ing by indication, balance the risk of mortality from
bleeding versus a potential benefit on breast cancer
survival, and determine a causal relationship between
breast cancer prognosis and ASA.
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